company background image
GH

Guardant Health NasdaqGS:GH Stock Report

Last Price

US$35.09

Market Cap

US$3.6b

7D

14.6%

1Y

-68.9%

Updated

16 May, 2022

Data

Company Financials +
GH fundamental analysis
Snowflake Score
Valuation0/6
Future Growth2/6
Past Performance0/6
Financial Health4/6
Dividends0/6

GH Stock Overview

Guardant Health, Inc., a precision oncology company, provides blood tests, data sets, and analytics in the United States and internationally.

Guardant Health Competitors

Price History & Performance

Summary of all time highs, changes and price drops for Guardant Health
Historical stock prices
Current Share PriceUS$35.09
52 Week HighUS$133.82
52 Week LowUS$27.65
Beta0.69
1 Month Change-51.26%
3 Month Change-51.52%
1 Year Change-68.85%
3 Year Change-55.17%
5 Year Changen/a
Change since IPO8.98%

Recent News & Updates

Apr 29
Guardant Health (NASDAQ:GH) Is Carrying A Fair Bit Of Debt

Guardant Health (NASDAQ:GH) Is Carrying A Fair Bit Of Debt

Some say volatility, rather than debt, is the best way to think about risk as an investor, but Warren Buffett famously...

Apr 14

Guardant Health: Leaping Growth With Epic

Amid a down market, Guardant shares are trading at a bargain to their estimated value. Meanwhile, Guardant continues to procure robust sales increases and narrowed its bottom line depreciation. The recent Epic deal for its diagnostics to reach over 250M patients is a transformative milestone to galvanize forward revenues.

Shareholder Returns

GHUS HealthcareUS Market
7D14.6%1.3%0.7%
1Y-68.9%4.8%-10.8%

Return vs Industry: GH underperformed the US Healthcare industry which returned 4% over the past year.

Return vs Market: GH underperformed the US Market which returned -10.4% over the past year.

Price Volatility

Is GH's price volatile compared to industry and market?
GH volatility
GH Average Weekly Movement15.6%
Healthcare Industry Average Movement10.1%
Market Average Movement7.8%
10% most volatile stocks in US Market16.8%
10% least volatile stocks in US Market2.9%

Stable Share Price: GH is more volatile than 75% of US stocks over the past 3 months, typically moving +/- 16% a week.

Volatility Over Time: GH's weekly volatility has increased from 10% to 16% over the past year.

About the Company

FoundedEmployeesCEOWebsite
20111,373Helmy Eltoukhyhttps://guardanthealth.com

Guardant Health, Inc., a precision oncology company, provides blood tests, data sets, and analytics in the United States and internationally. The company offers Guardant360, Guardant360 LDT, Guardant360 CDx, and GuardantOMNI liquid biopsy-based tests for advanced stage cancer; and GuardantINFORM, an in-silico research platform that comprise a clinical-genomic liquid biopsy dataset of advanced cancer patients. It is also developing LUNAR-2 test for the early detection of colorectal cancer in asymptomatic individuals eligible; and GuardantConnect, an integrated software-based solution for clinical and biopharmaceutical customers seeking to connect patients tested with the Guardant360 assay with actionable alterations with potentially relevant clinical trials.

Guardant Health Fundamentals Summary

How do Guardant Health's earnings and revenue compare to its market cap?
GH fundamental statistics
Market CapUS$3.58b
Earnings (TTM)-US$419.24m
Revenue (TTM)US$391.09m

9.1x

P/S Ratio

-8.5x

P/E Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report
GH income statement (TTM)
RevenueUS$391.09m
Cost of RevenueUS$126.15m
Gross ProfitUS$264.94m
Other ExpensesUS$684.18m
Earnings-US$419.24m

Last Reported Earnings

Mar 31, 2022

Next Earnings Date

n/a

Earnings per share (EPS)-4.11
Gross Margin67.74%
Net Profit Margin-107.20%
Debt/Equity Ratio213.0%

How did GH perform over the long term?

See historical performance and comparison

Valuation

Is Guardant Health undervalued compared to its fair value and its price relative to the market?

Valuation Score

0/6

Valuation Score 0/6

  • Below Fair Value

  • Significantly Below Fair Value

  • PE vs Industry

  • PE vs Market

  • PEG Ratio

  • PB vs Industry


6.71x

Price to Book (PB) ratio

Share Price vs. Fair Value

Below Fair Value: Insufficient data to calculate GH's fair value for valuation analysis.

Significantly Below Fair Value: Insufficient data to calculate GH's fair value for valuation analysis.


Price To Earnings Ratio

PE vs Industry: GH is unprofitable, so we can't compare its PE Ratio to the US Healthcare industry average.

PE vs Market: GH is unprofitable, so we can't compare its PE Ratio to the US market.


Price to Earnings Growth Ratio

PEG Ratio: Insufficient data to calculate GH's PEG Ratio to determine if it is good value.


Price to Book Ratio

PB vs Industry: GH is overvalued based on its PB Ratio (6.7x) compared to the US Healthcare industry average (2.5x).


Future Growth

How is Guardant Health forecast to perform in the next 1 to 3 years based on estimates from 13 analysts?

Future Growth Score

2/6

Future Growth Score 2/6

  • Earnings vs Savings Rate

  • Earnings vs Market

  • High Growth Earnings

  • Revenue vs Market

  • High Growth Revenue

  • Future ROE


18.6%

Forecasted annual earnings growth

Earnings and Revenue Growth Forecasts


Analyst Future Growth Forecasts

Earnings vs Savings Rate: GH is forecast to remain unprofitable over the next 3 years.

Earnings vs Market: GH is forecast to remain unprofitable over the next 3 years.

High Growth Earnings: GH is forecast to remain unprofitable over the next 3 years.

Revenue vs Market: GH's revenue (23.3% per year) is forecast to grow faster than the US market (8% per year).

High Growth Revenue: GH's revenue (23.3% per year) is forecast to grow faster than 20% per year.


Earnings per Share Growth Forecasts


Future Return on Equity

Future ROE: GH is forecast to be unprofitable in 3 years.


Past Performance

How has Guardant Health performed over the past 5 years?

Past Performance Score

0/6

Past Performance Score 0/6

  • Quality Earnings

  • Growing Profit Margin

  • Earnings Trend

  • Accelerating Growth

  • Earnings vs Industry

  • High ROE


-49.0%

Historical annual earnings growth

Earnings and Revenue History

Quality Earnings: GH is currently unprofitable.

Growing Profit Margin: GH is currently unprofitable.


Past Earnings Growth Analysis

Earnings Trend: GH is unprofitable, and losses have increased over the past 5 years at a rate of 49% per year.

Accelerating Growth: Unable to compare GH's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: GH is unprofitable, making it difficult to compare its past year earnings growth to the Healthcare industry (9.6%).


Return on Equity

High ROE: GH has a negative Return on Equity (-75.16%), as it is currently unprofitable.


Financial Health

How is Guardant Health's financial position?

Financial Health Score

4/6

Financial Health Score 4/6

  • Short Term Liabilities

  • Long Term Liabilities

  • Debt Level

  • Reducing Debt

  • Stable Cash Runway

  • Forecast Cash Runway

Financial Position Analysis

Short Term Liabilities: GH's short term assets ($1.1B) exceed its short term liabilities ($228.8M).

Long Term Liabilities: GH's short term assets ($1.1B) do not cover its long term liabilities ($1.4B).


Debt to Equity History and Analysis

Debt Level: GH's net debt to equity ratio (32.5%) is considered satisfactory.

Reducing Debt: GH's debt to equity ratio has increased from 9% to 213% over the past 5 years.


Balance Sheet


Cash Runway Analysis

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

Stable Cash Runway: GH has sufficient cash runway for more than 3 years based on its current free cash flow.

Forecast Cash Runway: GH has sufficient cash runway for 1.9 years if free cash flow continues to reduce at historical rates of 34.2% each year.


Dividend

What is Guardant Health current dividend yield, its reliability and sustainability?

Dividend Score

0/6

Dividend Score 0/6

  • Notable Dividend

  • High Dividend

  • Stable Dividend

  • Growing Dividend

  • Earnings Coverage

  • Future Dividend Coverage

Dividend Yield vs Market

Notable Dividend: Unable to evaluate GH's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.

High Dividend: Unable to evaluate GH's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.


Stability and Growth of Payments

Stable Dividend: Insufficient data to determine if GH's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if GH's dividend payments have been increasing.


Earnings Payout to Shareholders

Earnings Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.


Cash Payout to Shareholders

Cash Flow Coverage: Unable to calculate sustainability of dividends as GH has not reported any payouts.


Next Steps

Management

How experienced are the management team and are they aligned to shareholders interests?

2.0yrs

Average management tenure


CEO

Helmy Eltoukhy (42 yo)

9.33yrs

Tenure

US$13,665

Compensation

Dr. Helmy Eltoukhy, Ph D., has been the Chairman of the Board of Directors of Guardant Health, Inc. since August 05, 2021. He has been the Co-Chief Executive Officer at Guardant Health, Inc. since August 0...


CEO Compensation Analysis

Compensation vs Market: Helmy's total compensation ($USD13.67K) is below average for companies of similar size in the US market ($USD6.90M).

Compensation vs Earnings: Helmy's compensation has been consistent with company performance over the past year.


Leadership Team

Experienced Management: GH's management team is considered experienced (2 years average tenure).


Board Members

Experienced Board: GH's board of directors are considered experienced (4 years average tenure).


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.


Recent Insider Transactions

Ownership Breakdown

Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.


Top Shareholders

Company Information

Guardant Health, Inc.'s employee growth, exchange listings and data sources


Key Information

  • Name: Guardant Health, Inc.
  • Ticker: GH
  • Exchange: NasdaqGS
  • Founded: 2011
  • Industry: Health Care Services
  • Sector: Healthcare
  • Implied Market Cap: US$3.576b
  • Shares outstanding: 101.92m
  • Website: https://guardanthealth.com

Number of Employees


Location

  • Guardant Health, Inc.
  • 505 Penobscot Drive
  • Redwood City
  • California
  • 94063
  • United States

Listings


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2022/05/16 00:00
End of Day Share Price2022/05/16 00:00
Earnings2022/03/31
Annual Earnings2021/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.